Ace Investor Ashish Kacholia invests in TechInvention Lifecare

New Delhi: Ace Investor Ashish Kacholia has invested in TechInvention Lifecare Limited, a vaccine focussed biotechnology company headquartered in Mumbai.

The investment is to primarily fund TechInvention’s upcoming state-of-the-art NexGen Vaccine Manufacturing facility in Navi Mumbai. The facility is designed to scale-up & manufacture vaccines from its robust R&D portfolio of vaccine candidates encompassing contemporary platforms such as recombinant subunit, conjugates, VLP (virus-like particles), adenoviral vector & mRNA platforms.

Commenting on the investment, Mr Kacholia said: “We are delighted to support TechInvention in getting life-saving, innovative vaccines commercialized & reach millions across India & beyond. The founders of TechInvention are techno-commercially savvy & together we hope to build a high-quality business over the next few years”.

Syed S. Ahmed, Founder & CEO of TechInvention Lifecare Limited, added: “We are delighted to have Mr. Kacholia’s confidence in our vision & his participation is an assurance of the advancement of our Manufacturing facility project titled –‘Global Collaborative Centre for Medical Counter Measures (GCMC’). His belief in our mission reinforces India’s role as a trusted enabler of equitable health solutions for low & middle–income countries (LMICs).”

 Since inception, TechInvention has demonstrated steady growth, achieving a 65% CAGR in revenue. The company is now entering into Orbit Next, driven by its commitment to developing novel human vaccines that prevent infectious diseases & enhance global health resilience.

In recognition of its contribution to global health innovation & achievements, TechInvention has featured in Forbes India’s Top 200 Companies with Global Business Potential (2024), recipient of the SME Biopharma Company of the Year Award (2025), and rated as a “Lowest-Risk SME” by Dun & Bradstreet (2025).

The partnership with Mr Kacholia marks a significant milestone in TechInvention’s journey, not just as an investment, but as a strong endorsement of our vision to combine biotechnology & sustainability enabling equitable access & drive change on a global scale.